Patrick Groothuis

Patrick Groothuis

Company: Byondis

Job title: Principal Scientist - In Vivo Pharmacology, Toxicology, Drug Metabolism & Pharmacokinetics


Preclinical Profile of SYD1875, a Novel Site-Specifically Conjugated Anti-5T4 Antibody Drug Conjugate 6:00 pm

SYD1875 comprises a humanized, HC41-cysteine-engineered IgG1 monoclonal antibody that targets 5T4 SYD1875 is site-specifically conjugated to a proprietary cleavable synthetic duocarmycin-based linker-drug (vc-seco-DUBA), which yields a homogeneous and stable ADC with favorable physicochemical properties and manufacturability SYD1875 is a potent ADC with anti-tumor activity in multiple solid tumor types with high, moderate and low 5T4…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.